PhRMA backs Novartis' stance on punitive damages

10/6/2013 | Forbes

The Supreme Court could decide to review a case involving the question of whether drugmakers should be exempt from punitive damages in state product-liability lawsuits because the penalties overstep the FDA's enforcement powers. The fines that the FDA can levy could be greatly surpassed by punitive-damages awards, which put "enforcement discretion in the hands of tort plaintiffs who act as a private attorney general under the law," according to a brief from the drugmaker. The Pharmaceutical Research and Manufacturers of America has filed a friend-of-the-court brief in support of Novartis.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ